IUGR is a major cause of infant mortality & morbidity worldwide. The current management of IUGR being empirical & aimed of selecting a safe time for delivery. Acknowledging, the beneficial effect of L-arginine on endothelial vasculature by producing NO through L-Arginine/No Pathway by sterocospeicific enzyme NO SYNTHETASE, & arginine deficiency may play an important role in causation of IUGR. Starting from 3^rd wk of therapy, the umbilical artery pulsatility index were significantly lower in l-arginine then in placebo group. Treatment with L-arginine caused significant increase of middle cerebral artery pulsatility indices & cerebro placental ratio values. The present study showed that neonates delivered in L-arginine group had higher Apgar score. Supplementary t/t with oral L-arginine seems to be promising in improving fetal well bring & neonatal outcome as well as in prolonging pregnancy complicated with preeclampsia.

1. Divon MY, Hsu HW. Maternal and fetal blood flow velocity waveforms in intrauterine growth retardation. Clin Obstet Gynecol. 1992;35:156-171.
2. Biswas R, Dasgupta A, Sinha RN, Chaudhri RN. An epidemiological study of low birth weight newborns in the district of puruliya, West Bengal, India 2008;52(2)65-71.
3. Gluckman PD, Hanson MA. The consequences of being born small: an adaptive perspective. Horns Res. 2006;65:5-14.
4. Mari G, Hanif F. Intrauterine growth restriction: how to manage and when to deliver. Clin Obstet Gynecol. 2007; 50:497-509.
5. Sankaran S, Kyle PM. Aetiology and pathogenesis of IUGR. Best Pract Res Clin Obstet Gynaecol. 2009;23(6)765-777.

Dr Ritu Kumari

Senior Resident, Patna Medical College & Hospital, Patna